Table 2 Interventions and abbreviations for eligible studies
Author | Year | Study register/short name | Intervention | Abbr. | Control | Abbr. |
|---|---|---|---|---|---|---|
Yan Zhang [22] | 2013 | NA | Adriamycin; cisplatin; ifosfamide; recombinant human endostatin | APIR | Adriamycin; cisplatin; ifosfamide | API |
Neyssa M. Marina [23] | 2016 | EURAMOS-1 | Adriamycin; methotrexate; cisplatin | AMP | Adriamycin; methotrexate; cisplatin; ifosfamide; etoposide | AMPIE |
Sophie Piperno-Neumann [24] | 2016 | OS2006 | Methotrexate; ifosfamide; etoposide; zoledronate | MIEZ | Methotrexate; ifosfamide; etoposide | MIE |
Adriamycin; cisplatin; ifosfamide; zoledronate | APIZ | Adriamycin; cisplatin; ifosfamide | API | |||
Stefan S. Bielack [25] | 2015 | EURAMOS-1 | Adriamycin; methotrexate; cisplatin; interferonα-2β | AMPF | Adriamycin; methotrexate; cisplatin | AMP |
Alessandra Longhi [26] | 2014 | EudraCT:2006-002676-18 | Viscum album | V | Etoposide | E |
J.S. Whelan [27] | 2012 | EOI (BO02/80831) | Adriamycin; methotrexate; cisplatin | AMP | Adriamycin; cisplatin | AP |
EOI (BO03/80861) | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; cisplatin; vincristine | ABCDMPL | Adriamycin; cisplatin | AP | ||
Hui Zhao [28] | 2010 | NA | Cisplatin; pirarubicin | PT | Ifosfamide; pirarubicin | IT |
Alexander J. Chou [29] | 2009 | CCG/POG (INT-0133) | Adriamycin; methotrexate; cisplatin | AMP | Adriamycin; cisplatin; methotrexate; ifosfamide | AMPI |
Paul A. Meyers [30] | 2008 | CCG/POG (INT-0133) | Adriamycin; methotrexate; cisplatin | AMP | Adriamycin; cisplatin; methotrexate; ifosfamide | AMPI |
Marie-Cecile Le Deley [31] | 2007 | SFOP-OS94 (NCT00180908) | Adriamycin; methotrexate | AM | Methotrexate; ifosfamide; etoposide | MIE |
Paul A. Meyers [32] | 1998 | MSKCC (T12) protocol | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; cisplatin | ABCDMP | Bleomycin; cyclophosphamide; dactinomycin; methotrexate; | BCDM |
Robert L. Souhami [33] | 1997 | EOI (T10) protocol | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; vincristine | ABCDMPL | Adriamycin; cisplatin | AP |
Michael P. Link [34] | 1993 | MIOS | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; cisplatin | ABCDMP | Blank | Blank |
John H. Edmonson [35] | 1984 | Mayo Clinic | Methotrexate; vincristine | ML | Blank | Blank |
K. Winkler [36] | 1984 | COSS-80 | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; interferon | ABCDMF | Adriamycin; methotrexate; cisplatin; interferon | AMPF |
Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; | ABCDM | Adriamycin; methotrexate; cisplatin | AMP | |||
F. Eilber [37] | 1987 | NA | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; | ABCDM | Blank | Blank |
D.R. Sweetnam [38] | 1986 | NA | Adriamycin; methotrexate; vincristine | AML | Methotrexate; vincristine | ML |
K. Winkler [39] | 1988 | COSS-82 | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; cisplatin; ifosfamide | ABCDMPI | Adriamycin; bleomycin; cyclophosphamide; dactinomycin; methotrexate; cisplatin; | ABCDMP |
Vivien H.C. Bramwell [40] | 1992 | EOI | Adriamycin; methotrexate; cisplatin | AMP | Adriamycin; cisplatin | AP |
John C. Ivins [41] | 1976 | Mayo Clinic | Transfer factor | N | Adriamycin; methotrexate; vincristine | AML |
C. Jasmin [42] | 1978 | EORTC | Adriamycin; cyclophosphamide; methotrexate; vincristine | ACML | Adriamycin; methotrexate; cyclophosphamide; alkeran | ACMK |
Gilchrist GS [43] | 1978 | NA | Adriamycin; methotrexate; vincristine | AML | Transfer factor | N |
J.M.V. Burgers [44] | 1988 | EORTC-SIOP03 (20781) | Adriamycin; cyclophosphamide; methotrexate; vincristine | ACML | Blank | Blank |